Market Closed -
Nasdaq Stockholm
11:23:35 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
0.4745
SEK
|
+0.96%
|
|
-5.10%
|
-9.27%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
970.5
|
1,230
|
854.4
|
480.6
|
451.4
|
477.9
|
-
|
-
|
Enterprise Value (EV)
1 |
674.6
|
1,081
|
735.8
|
490.7
|
331.5
|
418.6
|
286.1
|
7.912
|
P/E ratio
|
-7.01
x
|
-6.32
x
|
-5.87
x
|
-3.44
x
|
-2.38
x
|
-3.95
x
|
3.8
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
27,562
x
|
142
x
|
15.2
x
|
-
|
1.81
x
|
-
|
EV / Revenue
|
-
|
-
|
23,735
x
|
145
x
|
11.2
x
|
-
|
1.08
x
|
-
|
EV / EBITDA
|
-5.1
x
|
-
|
-5.66
x
|
-3.73
x
|
-3.69
x
|
-3.25
x
|
2.14
x
|
-0.21
x
|
EV / FCF
|
-
|
-
|
-5.28
x
|
-4.03
x
|
-1.88
x
|
-4.76
x
|
0.73
x
|
-0.21
x
|
FCF Yield
|
-
|
-
|
-18.9%
|
-24.8%
|
-53.3%
|
-21%
|
136%
|
-480%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
92,258
|
166,167
|
199,401
|
199,401
|
863,148
|
1,007,192
|
-
|
-
|
Reference price
2 |
10.52
|
7.400
|
4.285
|
2.410
|
0.5230
|
0.4745
|
0.4745
|
0.4745
|
Announcement Date
|
2/18/20
|
2/18/21
|
2/17/22
|
2/17/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
0.031
|
3.375
|
29.61
|
-
|
264
|
-
|
EBITDA
1 |
-132.3
|
-
|
-130.1
|
-131.5
|
-89.78
|
-128.7
|
133.4
|
-38
|
EBIT
1 |
-132.3
|
-86.03
|
-130.1
|
-133.7
|
-100.6
|
-129.6
|
132.5
|
-38
|
Operating Margin
|
-
|
-
|
-419,677.42%
|
-3,961.04%
|
-339.88%
|
-
|
50.2%
|
-
|
Earnings before Tax (EBT)
1 |
-134
|
-89.25
|
-133.4
|
-138.8
|
-101.6
|
-130
|
132
|
-38
|
Net income
1 |
-134
|
-89.25
|
-133.4
|
-138.8
|
-101.6
|
-130
|
132
|
-38
|
Net margin
|
-
|
-
|
-430,354.84%
|
-4,112.15%
|
-343.16%
|
-
|
50.01%
|
-
|
EPS
2 |
-1.500
|
-1.170
|
-0.7300
|
-0.7000
|
-0.2200
|
-0.1200
|
0.1250
|
-
|
Free Cash Flow
1 |
-
|
-
|
-139.4
|
-121.7
|
-176.6
|
-88
|
390
|
-38
|
FCF margin
|
-
|
-
|
-449,658.06%
|
-3,604.62%
|
-596.41%
|
-
|
147.73%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
292.31%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
295.37%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/18/20
|
2/18/21
|
2/17/22
|
2/17/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
10.2
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
296
|
149
|
119
|
-
|
120
|
59.3
|
192
|
470
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.0775
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-139
|
-122
|
-177
|
-88
|
390
|
-38
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-20.2%
|
-23.7%
|
-16.7%
|
-20%
|
46%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
1.36
|
12.3
|
10.2
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
4,390.32%
|
365.16%
|
34.48%
|
-
|
-
|
-
|
Announcement Date
|
2/18/20
|
2/18/21
|
2/17/22
|
2/17/23
|
2/14/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -9.27% | 43.59M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|